Table 6.
Comparison of results from index study with the published studies on utility of eltrombopag as second-line therapy in ITP
| Study | Tomas et al. 2015 (21) | Eser et al. 2016 (20) | Tomas et al. 2017 (32) | Çekdemir et al. 2019 (31) | Present study |
|---|---|---|---|---|---|
| Study design | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective |
| Number of patients (n) | 152 | 31 | 220 | 285 | 53 |
| Median age, years(range) | 63 (45-75) | 51 (33-59) | 62 (47-75) | 43.9 ± 20.6 | 35 (17-78) |
| Females, n (%) | 109 (72%) | 16 (51.6%) | 47 (41.6%) | 187 (65.6%) | 23 (43.4%) |
| Duration of ITP, months (range) | 81 (30-192) | - | 79 (31-193) | - | 2.06 year (32 days-14.23 year) |
| Median number of prior lines of therapy, n (range) | 3 (2-4) | 4 (3-5) | 3 (2-4) | - | 3 (1-8) |
| Prior splenectomy, n (%) | 104 (68%) | 24 (77.4) | 11 (11%) | - | 8 (15.09%) |
| Prior Rituximab, n (%) | 17 (23%) | 19 (61.3) | 47 (30.7%) | - | 16 (30.19%) |
| Overall response, n (%) | 135 (88.8%) | 26 (83.9%) | 127 (90%) | 247 (86.7%) | 81.1% (on day+90) |
| Median time to response | 12 days (9-13) | 16 days (8-28) | 13 days (7-18) | 14 days (3-210) | 35 days (28-50) |
| Follow up Median | 15 months | 29 weeks (11-74) | 15 months | 18 ± 6.4 months | Not reached |
| Sustained response | 75.2% at 15 months | - | 71% | - | |
| 1-year | 93.4% | ||||
| 3-year | 74.7% | ||||
| 5-year | 52.3% | ||||
| All ADRs* | 28 (18.4%) | - | 70 (31.8%) | 62 (21.8%) | 17 (32%) |
| ADRs ≥ gd3 | 2 (1.32%) | One SCD** | 15 (6.82%) | 18 (6.3%) One SCD* | 4 (7.55%) |
*
ADRs: adverse drug reactions;
**
SCD, sudden cardiac death.